Kinarus Therapeutics to host KOL event on Monday, June 27, to discuss therapies in wet Age-Related Macular Degeneration and potential advantages of KIN001
BASEL, Switzerland–(BUSINESS WIRE)–Kinarus Therapeutics Holding AG (SIX: KNRS) (“Kinarus”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of viral, respiratory, and ophthalmic diseases, announced today that it will host a key opinion leader (KOL) event for investors in Zurich on Monday, June 27, starting at 12:15 pm … [Read more…]